Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) News
Filter OSMT News Items
OSMT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OSMT News Highlights
- For OSMT, its 30 day story count is now at 5.
- Over the past 29 days, the trend for OSMT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about OSMT are JD, STAR and VIEW.
Latest OSMT News From Around the Web
Below are the latest news stories about Osmotica Pharmaceuticals plc that investors may wish to consider to help them evaluate OSMT as an investment opportunity.
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer and James “JD” Schaub, Chief Operating Officer, will host a video webcast to discuss |
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows: Date:Wednesday, January 19, 2022Time:8:30 a.m. ETWebcas |
H.C. Wainwright Thinks Osmotica Pharmaceuticals’ Stock is Going to RecoverH.C. Wainwright analyst Douglas Tsao initiated coverage with a Buy rating on Osmotica Pharmaceuticals (OSMT – Research Report) today and set a price target of $5.00. The company's shares closed last Wednesday at $1.06, close to its 52-week low of $0.98. According to TipRanks.com, Tsao is a 4-star analyst with an average return of 8.8% and a 47.6% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Osmotica Pharmaceuticals with a $5.75 average price target. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Executive VP & COO James Schaub Just Bought 30% More Shares In Osmotica Pharmaceuticals plc (NASDAQ:OSMT)Potential Osmotica Pharmaceuticals plc ( NASDAQ:OSMT ) shareholders may wish to note that the Executive VP & COO, James... |
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceBRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows: Date:Monday, January 10, 2022On Demand Time:7:00AM ETWebcast:https://journey.ct.events/view/b39a70c0-7058 |
Osmotica Pharmaceuticals (NASDAQ:OSMT shareholders incur further losses as stock declines 13% this week, taking three-year losses to 78%As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an... |
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue EstimatesOsmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? |
Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business UpdateThird quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with introduction of Direct Dispense program in eyecare and formation of Aesthetics business unit Sale of legacy business and capital raises streamlined business and strengthened balance sheet BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, tod |
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows: Date:Thursday, November 18, 2021On Demand Time:8:00AM GMT (3:00AM ET)Webcast:https://wsw.com/webcast/ |